Paris (France), May 16, 2023 – 06:00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX), a clinical-stage biotechnology company […]

Paris (France), April 28, 2023 – 9.00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX), hereafter “Onxeo” or the […]

Phase 1b/2 trial of AsiDNATM in combination with olaparib in the United States in recurrent ovarian, breast and metastatic castration-resistant […]

Paris (France), April 21, 2023 – 8:30 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX), a clinical-stage biotechnology company […]

The annual general meeting will be held on June 6, 2023   Paris (France), March 14, 2023 – 6:00 pm […]

Paris (France), April 14, 2023 – 5:35 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX), a clinical-stage biotechnology company […]

Paris (France), February 6, 2023 – 7:30 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX), (“Onxeo” or “the Company”), […]

OX425 is a novel DDR Decoy Agonist which also mediates multiple immunostimulatory effects, making it a promising candidate for combination […]

Refocusing R&D efforts as well as accelerating preclinical and clinical programs globally Cash position of €26.9 million as of June […]

Paris (France), September 1st, 2022 – 8 pm CEST – Onxeo S.A. (Euronext Growth: ALONX, Nasdaq First North[1]: ONXEO), a […]

Company to submit delisting request to Nasdaq   Paris (France), August 17, 2022 – 08:00 pm CEST – Onxeo S.A. […]

Paris (France), July 29, 2022 – 06:30 pm CEST – Onxeo S.A. (Euronext Growth: ALONX, Nasdaq First North: ONXEO), a […]

Paris (France), July 12, 2022 – 07:00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: […]

Onxeo to initiate its first phase 1b/2 trial in the United States in patients with solid tumors   Paris (France), […]

All resolutions voted in accordance with Board of Directors’ recommendations Khalil Barrage, Managing Director of Invus’ public equity investments division, […]

Agarwal is Currently Chairwoman of Onxeo’s Board, a Position Held Since June 2021 Company Outlines Development Strategy Plans Including Preparation […]

Cash position of €17.9 million as of December 31, 2021 Additional financing of €12 million subscribed by historical shareholders Invus […]

AsiDNA™ proven to overcome resistance to tyrosine kinase inhibitors in lung cancer models AsiDNA™ proven to protect healthy cells when […]

Paris (France), January 3rd, 2022 – 6:00 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), (“Onxeo” or “the Company”), […]

Paris (France), January 13, 2022 – 6 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), […]

These pioneering data were presented at ESMO Targeted Anticancer Therapies Congress 2022   Paris (France), March 9, 2022 – 7:00 […]